Chinese Biopharma Firm Alphamab Oncology Gets $60M In Series B Round

Login to View

Alphamab Oncology, a Chinese biopharma company that specializes in the development of innovative biologics for cancer therapy, announced on Tuesday that it has secured US$60 million in a series B round of financing led by New York-based asset management firm Hudson Bay Capital Management.

China Money Network

Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech

Want to read this important story?

Access Over 11,000 stories and data posts over the past 8 years!

Register Now

Already have an account or paid subscription? Log in